Literature DB >> 26138439

Advanced stages of PD: interventional therapies and related patient-centered care.

Rejko Krüger1,2, Rüdiger Hilker3, Christian Winkler4,5, Michael Lorrain6, Matthias Hahne7, Christoph Redecker8, Paul Lingor9, Wolfgang H Jost10.   

Abstract

During the last decades, symptomatic treatment of motor symptoms of Parkinson's disease (PD) improved continuously and is reflected by long-range independency of the patient during the disease course. However, advanced stages of PD still represent an important challenge to patients, caregivers and treating physicians. In patients with advanced PD, interventional therapy strategies are increasingly applied. These device-related treatment strategies using pump-based continuous dopaminergic stimulation (CDS) or deep brain stimulation (DBS) opened new treatment options especially if motor complications predominate. Well-designed clinical studies on these interventional therapeutic approaches provided class 1 evidence for the efficacy of DBS and CDS in advanced PD and opened new perspectives for their use in earlier disease stages also. Therefore, careful selection of patients amenable to the (semi)invasive therapy options becomes more and more important and requires an interdisciplinary setting that accounts for (i) optimal patient information and awareness, (ii) selection of best individual treatment modality, (iii) training of relatives and caregivers, (iv) management of complications, and (v) follow-up care. Here, we address these topics by summarizing current state-of-the-art in patient selection, providing specificities of treatment options and troubleshooting, and defining steps towards an optimized patient-centered care. Interventional therapies pioneer in the area of individualized treatment approaches for PD, and may be complemented in the future by biomarker-based improved stratification and by closed-loop systems for adaptive therapeutic strategies. In the present review, we summarize the proceedings of an Expert Workshop on Parkinson's disease held on November 22, 2014 in Frankfurt, Germany.

Entities:  

Keywords:  Apomorphine; Deep brain stimulation; Levodopa-carbidopa intestinal gel; Motor complications; Parkinson’s disease; Patient-centred care

Mesh:

Substances:

Year:  2015        PMID: 26138439     DOI: 10.1007/s00702-015-1418-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  55 in total

Review 1.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 2.  Surgical treatment of Parkinson disease: past, present, and future.

Authors:  Andrew P Duker; Alberto J Espay
Journal:  Neurol Clin       Date:  2013-04-04       Impact factor: 3.806

3.  A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.

Authors:  Hilary L Tyne; Jan Parsons; Ann Sinnott; Susan H Fox; Nicholas A Fletcher; Malcolm J Steiger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

4.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

5.  Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers.

Authors:  Michael S Okun; Michele Tagliati; Michael Pourfar; Hubert H Fernandez; Ramon L Rodriguez; Ron L Alterman; Kelly D Foote
Journal:  Arch Neurol       Date:  2005-06-13

6.  Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.

Authors:  A J Hughes; S Bishop; B Kleedorfer; N Turjanski; W Fernandez; A J Lees; G M Stern
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

7.  Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.

Authors:  Valerie C Anderson; Kim J Burchiel; Penelope Hogarth; Jacques Favre; John P Hammerstad
Journal:  Arch Neurol       Date:  2005-04

8.  Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years.

Authors:  H Russmann; J Ghika; J-G Villemure; B Robert; J Bogousslavsky; P R Burkhard; F J G Vingerhoets
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

9.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

Authors:  Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  N Engl J Med       Date:  2010-06-03       Impact factor: 91.245

10.  Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.

Authors:  Michael Schüpbach; Ebba Lohmann; Mathieu Anheim; Suzanne Lesage; Virginie Czernecki; Sadek Yaici; Yulia Worbe; Perrine Charles; Marie-Laure Welter; Pierre Pollak; Alexandra Dürr; Yves Agid; Alexis Brice
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

View more
  16 in total

1.  Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.

Authors:  Carsten Buhmann; R Hilker; P Lingor; C Schrader; J Schwarz; M Wolz; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-22       Impact factor: 3.575

2.  Complex therapies for advanced Parkinson's disease: what is the role of doctor-patient communication?

Authors:  Elisa Montanaro; Carlo Alberto Artusi; Maurizio Zibetti; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2019-06-28       Impact factor: 3.307

Review 3.  A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.

Authors:  Philippe A Salles; James Liao; Umar Shuaib; Ignacio F Mata; Hubert H Fernandez
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

4.  Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients.

Authors:  Viorelia Adelina Constantin; József Attila Szász; Károly Orbán-Kis; Elena Cecilia Rosca; Maria Popovici; Amalia Cornea; Ligia Ariana Bancu; Marius Ciorba; István Mihály; Előd Nagy; Szabolcs Szatmári; Mihaela Simu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-28       Impact factor: 2.570

Review 5.  Classification of advanced stages of Parkinson's disease: translation into stratified treatments.

Authors:  Rejko Krüger; Jochen Klucken; Daniel Weiss; Lars Tönges; Pierre Kolber; Stefan Unterecker; Michael Lorrain; Horst Baas; Thomas Müller; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2017-03-24       Impact factor: 3.575

6.  The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis.

Authors:  Geraldine Hipp; Michel Vaillant; Nico J Diederich; Kirsten Roomp; Venkata P Satagopam; Peter Banda; Estelle Sandt; Kathleen Mommaerts; Sabine K Schmitz; Laura Longhino; Alexandra Schweicher; Anne-Marie Hanff; Béatrice Nicolai; Pierre Kolber; Dorothea Reiter; Lukas Pavelka; Sylvia Binck; Claire Pauly; Lars Geffers; Fay Betsou; Manon Gantenbein; Jochen Klucken; Thomas Gasser; Michele T Hu; Rudi Balling; Rejko Krüger
Journal:  Front Aging Neurosci       Date:  2018-10-29       Impact factor: 5.750

Review 7.  Update on the Management of Parkinson's Disease for General Neurologists.

Authors:  Zvezdan Pirtošek; Ovidiu Bajenaru; Norbert Kovács; Ivan Milanov; Maja Relja; Matej Skorvanek
Journal:  Parkinsons Dis       Date:  2020-03-26

8.  Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study.

Authors:  Bruna Meira; Bertrand Degos; Elise Corsetti; Mohamed Doulazmi; Emeline Berthelot; Clara Virbel-Fleischman; Pauline Dodet; Aurélie Méneret; Louise-Laure Mariani; Cécile Delorme; Florence Cormier-Dequaire; David Bendetowicz; Nicolas Villain; Clément Tarrano; Lise Mantisi; Hélène Letrillart; Céline Louapre; Eavan McGovern; Yulia Worbe; David Grabli; Marie Vidailhet; Elodie Hainque; Emmanuel Roze
Journal:  NPJ Parkinsons Dis       Date:  2021-06-11

9.  The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.

Authors:  Michal Lubomski; Xiangnan Xu; Jean Y H Yang; Carolyn M Sue; Ryan L Davis; Andrew J Holmes
Journal:  J Neurol       Date:  2021-06-15       Impact factor: 6.682

Review 10.  Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners.

Authors:  Michelle Burack; Jason Aldred; Cindy Zadikoff; Arvydas Vanagunas; Kevin Klos; Bahri Bilir; Hubert H Fernandez; David G Standaert
Journal:  Mov Disord Clin Pract       Date:  2018-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.